5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 1, 2005, Pages 29-35

  Qiao, Jennifer X ^a   Cheng, Xuhong ^a   Modi, Dilip P ^a   Rossi, Karen A ^a   Luettgen, Joseph M ^a   Knabb, Robert M ^a   Jadhav, Prabhakar K ^a   Wexler, Ruth R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulant; Benzo b thiophene; Factor IXa

Indexed keywords

5 AMIDINOBENZO[B]THIOPHENE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9A; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

FACTOR IXA; FACTOR XA; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 9644266671     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.10.045     Document Type: Article

References (23)

1. G. van Dieijen, G. Tans, J. Rosing, and H.C. Hemker J. Biol. Chem. 256 1981 3433
2. E.J. Duffy, E.T. Parker, V.P. Mutucumarana, A.E. Johnson, and P. Lollar J. Biol. Chem. 267 1992 17006
3. E.J. Duffy, and P. Lollar J. Biol. Chem. 267 1992 7821
4. C.R. Benedict, J. Ryan, and B. Wolitzky J. Clin. Invest. 88 1991 1760
5. J. Himber, C.J. Refino, L. Burcklen, S. Roux, and D. Kirchhofer Thromb. Haemostasis 85 2001 475
6. G.Z. Feuerstein, A. Patel, J.R. Toomey, P. Bugelski, A.J. Nichols, W.R. Church, R. Valocik, P. Koster, A. Baker, and M.N. Blackburn Arterioscl. Throm. Vas. 19 1999 2554
7. G.Z. Feuerstein, J.R. Toomey, R. Valocik, P. Koster, and A. Patel Thromb. Haemostasis 82 1999 1443
8. T. Spanier, M.C. Oz, O.P. Minanov, R. Simantov, W. Kisiel, D.M. Stern, E.A. Rose, and A.M. Schmidt J. Thorac. Cardiovasc. Surg. 115 1998 1179
9. C.J. Refino, S. Jeet, L. DeGuzman, S. Bunting, and D. Kirchhofer Thromb. Haemostatsis 82 1999 1188
10. Dominguez, C.; Han, Q.; Duffy, D. E.; Park, J. M.; Quan, M. L.; Rossi, K.; Wexler, R. U.S. 5,886,191, 1999
11. The modification of 5-amidinoindole analogs toward potent and selective fIXa inhibitors is described in the following paper: D.G. Batt, J.X. Qiao, D.P. Modi, G.C. Houghton, D.A. Pierson, K.A. Rossi, J.M. Luettgen, R.M. Knabb, P.K. Jadhav, and R.R. Wexler Bioorg. Med. Chem. Lett. 14 2004 5269
12. F. Jin, and P.N. Confalone Tetrahedron Lett. 41 2000 3271
13. P.A. Ple, and L.J. Marnett J. Heterocycl. Chem. 25 1988 1271
14. T. Aoyama, and T. Shioiri Chem. Pharm. Bull. 29 1981 3249
15. H.T.J. Chan, J.A. Elix, and B.A. Ferguson Synth. Commun. 2 1972 409
16. J.H. Meyer, and P.A. Bartlett J. Am. Chem. Soc. 120 1998 4600
17. Y. Zhou, and M.E. Johnson J. Mol. Recognit. 12 1999 235
18. SAR and crystal structure of a benzimidazole analog of factor Xa inhibitor SN-429 in factor IXa is described in the following paper: J.M. Smallheer, R.A. Alexander, J. Wang, S. Wang, S. Nakajima, K.A. Rossi, A. Smallwood, F. Barbera, D. Burdick, J.M. Luettgen, R.M. Knabb, R.R. Wexler, and P.K. Jadhav Bioorg. Med. Chem. Lett. 14 2004 5263
19. i assays are based on chromogenic substrates specific for the enzyme being evaluated by using analogous protocols as described by C. Kettner, L. Mersinger, and R. Knabb J. Biol. Chem. 265 1990 18289
20. m = 1800 μM
21. We employed an in-house protocol16 that generated millions of 2, 3, and 4 point pharmacophores from the entire fIXa dataset. Once the pharmacophores were generated, the most 'informative' pharmacophores were selected based on activity versus inactivity as well as diversity. A library of amines were selected through 'infopicking' of the most informative pharmacophores, resulting in a diverse and informative set
22. B.A. Katz, R. Mackman, C. Luong, K. Radika, A. Martelli, P.A. Sprengeler, J. Wang, H. Chan, and L. Wong Chem. Bio. 7 2000 299 312
23. J.L. Miller, E.K. Bradley, and S.L. Teig J. Chem. Inf. Comp. Sci. 43 2003 47 54